Section 5: Patient Safety and Quality Assurance

5PSQ-037

IMPORTANCE AND IMPACT OF PHARMACEUTICAL RECONCILIATION AT DISCHARGE IN THE ELDERLY PATIENT WITH POLYMEDICATION

5PSQ-036

MEDICATION ERRORS RELATED TO HIGH-ALERT MEDICATIONS IN A TERTIARY CARE PEDIATRIC HOSPITAL – AN ANALYSIS OF REGISTER-BASED DATA

5PSQ-035

MASS UNIFORMITY OF HARD CAPSULES: ROYAL SPANISH PHARMACOPOEIA VS UNITED STATES PHARMACOPOEIA

5PSQ-034

FIXED VS WEIGHT-BASED DOSING OF PEMBROLIZUMAB FOR PATIENTS UNDER 80 KG, BASED ON OBSERVED ADRS IN ONE CANCER SETTING

5PSQ-033

ANTIVIRAL TREATMENT DISCONTINUATION IN PATIENTS WITH HEPATITIS B

5PSQ-032

PHARMACIST INTEGRATION IN THE MULTIDISCIPLINARY EMERGENCY TEAM

5PSQ-031

ANALYSIS OF THE USE OF ISAVUCONAZOLE IN CRITICALLY ILL PATIENTS WHEN THE USE OF VORICONAZOLE IS INDICATED

5PSQ-030

SAFETY AND SECURITY OF CICLOSPORIN EYE DROPS IN PATIENTS WITH XEROPHTHALMIA

5PSQ-029

PERCEIVED EXPERIENCE OF PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS (HIV) AFTER IMPLEMENTING A TELEPHARMACY PROGRAMME

5PSQ-028

CDK 4/6 INHIBITORS - ANALYSIS OF POTENTIAL DRUG INTERACTIONS

5PSQ-027

APPROPRIATENESS OF PRESCRIPTION OF TRICYCLIC ANTIDEPRESSANTS ACCORDING TO STOPP CRITERIA

5PSQ-026

MEDICATION-RELATED OSTEONECROSIS OF THE JAWS AND CDK4/6 INHIBITORS

5PSQ-025

IMPACT AND EVALUATION OF PHARMACOKINETIC MONITORING IN PRIMARY CARE.

5PSQ-024

HAZARD VULNERABILITY ANALYSIS (HVA): EVALUATION OF RISK IN EXPERIMENTAL ONCOLOGICAL DRUGS COMPOUNDING

5PSQ-023

SEVERE PHOTOTOXICITY REACTION ASSOCIATED WITH VANDETANIB: A CASE REPORT

Pages